Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 03:52PM ET
Dollar change
Percentage change
IndexRUT P/E42.44 EPS (ttm)0.87 Insider Own78.48% Shs Outstand37.58M Perf Week2.75%
Market Cap1.39B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.09M Perf Month5.38%
Income32.76M PEG- EPS next Q0.30 Inst Own13.59% Short Float / Ratio1.87% / 6.07 Perf Quarter-2.35%
Sales592.89M P/S2.34 EPS this Y61.76% Inst Trans0.50% Short Interest0.15M Perf Half Y-5.61%
Book/sh46.50 P/B0.80 EPS next Y- ROA1.55% Target Price35.00 Perf Year25.94%
Cash/sh24.14 P/C1.53 EPS next 5Y-12.95% ROE1.90% 52W Range22.89 - 42.22 Perf YTD27.38%
Dividend- P/FCF14.25 EPS past 5Y-33.64% ROI1.87% 52W High-12.39% Beta0.63
Dividend %- Quick Ratio3.14 Sales past 5Y-2.62% Gross Margin46.80% 52W Low61.60% ATR0.95
Employees1554 Current Ratio3.71 Sales Q/Q13.57% Oper. Margin1.24% RSI (14)57.13 Volatility2.08% 2.82%
OptionableYes Debt/Eq0.00 EPS Q/Q404.01% Profit Margin5.53% Rel Volume0.52 Prev Close36.74
ShortableYes LT Debt/Eq0.00 EarningsOct 26 AMC Payout0.00% Avg Volume24.90K Price36.99
Recom1.00 SMA202.66% SMA503.88% SMA2009.52% Volume12,780 Change0.68%
Date Action Analyst Rating Change Price Target Change
Jul-27-20Reiterated H.C. Wainwright Buy $96 → $82
Feb-04-20Reiterated H.C. Wainwright Buy $110 → $94
Nov-05-19Reiterated H.C. Wainwright Buy $105 → $110
Mar-12-18Initiated H.C. Wainwright Buy $124
May-23-17Downgrade Credit Suisse Outperform → Neutral
Oct-26-23 05:12PM
Oct-19-23 04:30PM
Jul-27-23 05:32AM
Jul-26-23 08:36PM
04:00PM Loading…
Jul-19-23 04:00PM
Jun-30-23 09:00AM
May-30-23 12:25PM
May-23-23 07:28PM
May-18-23 04:46PM
Apr-17-23 01:35PM
Jan-27-23 06:01AM
Jan-24-23 05:43PM
05:02PM Loading…
Jan-19-23 05:02PM
Oct-27-22 07:55PM
Oct-24-22 12:37PM
Oct-12-22 10:58AM
Aug-11-22 06:17PM
Jul-27-22 07:05PM
Jul-26-22 04:10PM
Jul-06-22 06:10AM
May-26-22 07:00PM
May-23-22 05:35PM
May-20-22 07:00PM
May-17-22 08:15AM
09:05AM Loading…
May-16-22 09:05AM
May-13-22 09:55AM
May-12-22 08:15AM
May-05-22 10:29AM
May-04-22 08:45AM
Feb-28-22 06:19PM
Feb-22-22 09:23AM
Jan-27-22 07:15PM
Jan-25-22 08:11AM
Jan-20-22 08:45PM
Jan-19-22 03:01PM
Jan-05-22 07:48AM
Dec-01-21 05:05PM
Nov-15-21 12:15PM
Oct-28-21 06:45PM
Oct-27-21 11:18AM
Oct-21-21 01:01PM
Oct-20-21 03:03PM
Jul-29-21 07:44AM
Jul-27-21 08:45PM
Jul-20-21 09:05PM
Jul-19-21 06:49AM
Jul-14-21 05:54PM
Jun-18-21 10:00AM
May-19-21 05:30PM
May-12-21 05:58PM
Mar-09-21 05:37AM
Jan-27-21 05:46PM
Jan-20-21 08:28PM
Dec-12-20 07:48PM
Oct-29-20 06:00AM
Oct-28-20 06:45PM
Oct-21-20 06:44PM
Sep-28-20 01:01PM
Sep-10-20 03:19PM
Jul-29-20 06:55PM
Jul-23-20 04:32PM
Jul-22-20 02:37PM
Jun-25-20 06:45PM
Jun-19-20 09:30AM
May-29-20 05:41PM
May-20-20 06:00AM
May-19-20 06:45PM
May-12-20 07:37PM
May-06-20 10:09AM
Apr-06-20 12:26PM
Mar-27-20 10:46AM
Mar-22-20 10:35AM
Mar-04-20 04:33PM
Feb-20-20 05:54PM
Feb-05-20 12:45PM
Feb-03-20 06:35PM
Jan-28-20 06:19PM
Jan-16-20 12:44PM
Jan-10-20 03:00PM
Dec-19-19 06:27PM
Dec-17-19 09:23PM
Dec-16-19 03:55PM
Dec-06-19 08:45AM
Nov-29-19 08:39AM
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.